U.K. officials are shaking up their biomedical research industry in order to make the country a more attractive place for drug developers. A string of academic health science centers will combine academic medical research departments and teaching hospitals, copying a structure in the U.S. that has benefited researchers. And officials will highlight the trials that are being planned for new drugs, making it easier for developers to recruit patients for their studies. Pfizer had to pull out of four planned trials in the U.K. after it was unable to find a sufficient number of patients who fit the profile.
- read the report from the Financial Times
PLUS: U.K. officials have nailed down a big part of the funding needed for a new "laboratory of the future" that will cost close to $400 million to build. Report